CL2019002922A1 - Anticuerpos anti-péptido beta amiloide n3pglu y sus usos. - Google Patents

Anticuerpos anti-péptido beta amiloide n3pglu y sus usos.

Info

Publication number
CL2019002922A1
CL2019002922A1 CL2019002922A CL2019002922A CL2019002922A1 CL 2019002922 A1 CL2019002922 A1 CL 2019002922A1 CL 2019002922 A CL2019002922 A CL 2019002922A CL 2019002922 A CL2019002922 A CL 2019002922A CL 2019002922 A1 CL2019002922 A1 CL 2019002922A1
Authority
CL
Chile
Prior art keywords
n3pglu
antibodies
clinical
amyloid beta
beta peptide
Prior art date
Application number
CL2019002922A
Other languages
English (en)
Inventor
Jirong Lu
Ying Tang
Ronald Bradley Demattos
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2019002922A1 publication Critical patent/CL2019002922A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICUERPOS CONTRA N3PGLU AΒ HUMANO, COMPOSICIONES QUE COMPRENDEN TALES ANTICUERPOS N3PGLU AΒ, Y MÉTODOS DE USO TALES ANTICUERPOS N3PGLU AΒ PARA EL TRATAMIENTO DE UNA ENFERMEDAD CARACTERIZADA POR LA DEPOSICIÓN DE AΒ QUE INCLUYE LA ENFERMEDAD DE ALZHEIMER CLÍNICA O PRECLÍNICA, SÍNDROME DE DOWN, Y ANGIOPATÍA AMILOIDE CEREBRAL CLÍNICA O PRECLÍNICA.
CL2019002922A 2017-04-20 2019-10-14 Anticuerpos anti-péptido beta amiloide n3pglu y sus usos. CL2019002922A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20

Publications (1)

Publication Number Publication Date
CL2019002922A1 true CL2019002922A1 (es) 2020-03-13

Family

ID=62111232

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002922A CL2019002922A1 (es) 2017-04-20 2019-10-14 Anticuerpos anti-péptido beta amiloide n3pglu y sus usos.

Country Status (28)

Country Link
US (3) US10647759B2 (es)
EP (1) EP3612559A1 (es)
JP (3) JP6900500B2 (es)
KR (2) KR102567295B1 (es)
CN (2) CN110582511B (es)
AR (1) AR111208A1 (es)
AU (2) AU2018255221B2 (es)
BR (1) BR112019018810A2 (es)
CA (1) CA3058482C (es)
CL (1) CL2019002922A1 (es)
CO (1) CO2019011349A2 (es)
CR (1) CR20190445A (es)
DO (1) DOP2019000241A (es)
EA (1) EA201992163A1 (es)
EC (1) ECSP19075146A (es)
IL (1) IL269003A (es)
JO (1) JOP20190247A1 (es)
MA (1) MA50144A (es)
MX (2) MX2019012445A (es)
NZ (1) NZ758066A (es)
PE (1) PE20200011A1 (es)
PH (1) PH12019502361A1 (es)
SA (1) SA519410311B1 (es)
SG (1) SG11201909022PA (es)
TW (2) TWI789644B (es)
UA (1) UA126806C2 (es)
WO (1) WO2018194951A1 (es)
ZA (1) ZA202007868B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
WO2020193644A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
WO2022072934A1 (en) 2020-10-02 2022-04-07 Eli Lilly And Company Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content
EP4274611A1 (en) 2021-01-11 2023-11-15 Eli Lilly and Company Anti-n3pglu amyloid beta antibodies and uses thereof
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
CN118139880A (zh) 2021-10-22 2024-06-04 伊莱利利公司 O-连接的n-乙酰葡糖胺水解酶(oga)抑制剂联合治疗
TW202336034A (zh) 2021-10-29 2023-09-16 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
AU2022376931A1 (en) 2021-10-29 2024-05-02 Eli Lilly Company Compounds and methods targeting interleukin-34
CA3236547A1 (en) 2021-10-29 2023-05-04 Marcio Chedid Compounds and methods targeting interleukin-34
WO2023076970A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
WO2024107683A1 (en) * 2022-11-17 2024-05-23 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA ANTIBODIES, DOSES, AND USES THEREOF

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100767146B1 (ko) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
KR101068289B1 (ko) 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
EP2310032A2 (en) 2008-06-12 2011-04-20 Affiris AG Compounds for treating symptoms associated with parkinson's disease
US20110182809A1 (en) 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
EA028427B1 (ru) 2008-07-21 2017-11-30 Пробиодруг Аг АНТИТЕЛО, СВЯЗЫВАЮЩЕЕСЯ С Aβ-ПЕПТИДАМИ ИЛИ ИХ ВАРИАНТАМИ, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО, И ЕГО ПРИМЕНЕНИЕ
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
PT3339323T (pt) * 2010-08-12 2020-01-14 Lilly Co Eli Anticorpos anti-péptido beta-amilóide n3pglu e seus usos
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
KR102405099B1 (ko) * 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها

Also Published As

Publication number Publication date
EA201992163A1 (ru) 2020-03-02
TWI705975B (zh) 2020-10-01
MX2022011817A (es) 2022-10-10
AU2018255221B2 (en) 2021-07-01
JP2023058623A (ja) 2023-04-25
MX2019012445A (es) 2020-01-13
US11078261B2 (en) 2021-08-03
PH12019502361A1 (en) 2020-07-13
ECSP19075146A (es) 2019-10-31
CN110582511B (zh) 2023-08-08
CR20190445A (es) 2019-11-06
JOP20190247A1 (ar) 2019-10-20
IL269003A (en) 2019-10-31
AU2021203927B2 (en) 2024-03-21
CN117024583A (zh) 2023-11-10
KR102352670B1 (ko) 2022-01-19
JP2020510081A (ja) 2020-04-02
SG11201909022PA (en) 2019-11-28
AU2018255221A1 (en) 2019-09-19
DOP2019000241A (es) 2019-10-15
SA519410311B1 (ar) 2022-03-20
TW202120541A (zh) 2021-06-01
US20210371509A1 (en) 2021-12-02
TW201902924A (zh) 2019-01-16
CA3058482A1 (en) 2018-10-25
TWI789644B (zh) 2023-01-11
CA3058482C (en) 2023-05-09
AR111208A1 (es) 2019-06-12
KR102567295B1 (ko) 2023-08-16
BR112019018810A2 (pt) 2020-05-05
PE20200011A1 (es) 2020-01-06
JP7227312B2 (ja) 2023-02-21
MA50144A (fr) 2020-07-29
KR20190129100A (ko) 2019-11-19
UA126806C2 (uk) 2023-02-08
JP6900500B2 (ja) 2021-07-07
JP2021151253A (ja) 2021-09-30
CN110582511A (zh) 2019-12-17
CO2019011349A2 (es) 2019-10-31
NZ758066A (en) 2022-10-28
KR20220011800A (ko) 2022-01-28
ZA202007868B (en) 2023-06-28
US20180305444A1 (en) 2018-10-25
AU2021203927A1 (en) 2021-07-08
US20200262902A1 (en) 2020-08-20
US10647759B2 (en) 2020-05-12
WO2018194951A1 (en) 2018-10-25
EP3612559A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
CL2019002922A1 (es) Anticuerpos anti-péptido beta amiloide n3pglu y sus usos.
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
ECSP20081591A (es) Proteínas de fusión que comprenden progranulina
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
SV2017005420A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112018011308A2 (pt) anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos
GT201700188A (es) Anticuerpos contra tau y sus usos
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
CL2019001293A1 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía.
UY34988A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
PE20230036A1 (es) Variantes de progranulina
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
CL2018003109A1 (es) Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.
GB2582683B (en) Composition for the care of human hair
BR112022004475A2 (pt) Proteínas de fusão nkg2d e usos das mesmas
CL2018003013A1 (es) Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson.
BR112017003200A2 (pt) anticorpos de potenciamento do fator h e seus usos
CL2022001712A1 (es) Variantes de progranulina
IT201700066486A1 (it) Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche
FR3052669B1 (fr) Prothese biologique destinee au traitement des hernies parastomales